# A case of eosinophilic pustular folliculitis involving palmoplantar successfully treated by apremilast

## TL;DR

A man with a rare skin condition called eosinophilic pustular folliculitis was successfully treated with apremilast, a drug that may be effective when traditional treatments fail.

## Contribution

This case demonstrates apremilast's effectiveness in treating EPF, especially in areas like palms and soles where treatment is challenging.

## Key findings

- Apremilast successfully treated EPF in a patient with lesions on the face, palms, and soles.
- The treatment was effective when traditional therapies had failed.
- This supports growing evidence for apremilast in managing EPF.

## Abstract

We presented a man with EPF involving the face, palms and soles, successfully treated by apremilast, a phosphodiesterase-4 (PDE4) inhibitor. Apremilast’s efficacy in this case adds to emerging evidence supporting its use in EPF, particularly when traditional treatments fail.

Eosinophilic pustular folliculitis (EPF) is a rare inflammatory dermatosis that predominantly affects seborrheic areas. The condition’s pathogenesis is linked to T helper 2-driven eosinophilic inflammation. We presented a man with EPF involving the face, palms and soles, successfully treated by apremilast, a phosphodiesterase-4 inhibitor. Apremilast’s efficacy in this case adds to emerging evidence supporting its use in EPF, particularly when traditional treatments fail.